Analyzing Vaccine Trials in Epidemics With Mild and Asymptomatic Infection.

ABSTRACT: Vaccine efficacy against susceptibility to infection (VES), regardless of symptoms, is an important endpoint of vaccine trials for pathogens with a high proportion of asymptomatic infection, because such infections may contribute to onward transmission and long-term sequelae, such as congenital Zika syndrome. However, estimating VES is resource-intensive. We aimed to identify approaches for accurately estimating VES when limited information is available and resources are constrained. We modeled an individually randomized vaccine trial by generating a network of individuals and simulating an epidemic. The disease natural history followed a "susceptible-exposed-infectious/symptomatic (or infectious/asymptomatic)-recovered" model. We then used 7 approaches to estimate VES, and we also estimat

SUBMITTER: Kahn R 

PROVIDER: S-EPMC6357804 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature